Q1 2024 Repligen Corp Earnings Call Transcript
Key Points
- Repligen Corp (RGEN) reported solid Q1 revenue of $151 million, aligning with expectations and maintaining guidance for the first half of 2024.
- Non-COVID Filtration orders increased by 20% year-on-year in Q1, with revenue up by more than 10%, indicating strong demand in this segment.
- Consumable orders showed a positive uptick, increasing by more than 10% both sequentially and year-on-year, suggesting recovery from previous destocking challenges.
- New modality revenue grew by over 15% compared to Q1 2023, with orders up 8%, highlighting growth in this innovative sector.
- Successful launch of new products like the fully automated GMP-ready filtration system RS10, and positive feedback at industry conferences, enhancing product portfolio and market competitiveness.
- Overall Q1 revenues were down $31 million or 17% year-on-year, primarily due to a $23 million decline in COVID-related revenue.
- Protein orders decreased by 30% as anticipated, continuing to pose significant challenges to revenue streams.
- CDMO orders were down both year-on-year and sequentially, indicating ongoing volatility and lack of a stable rebound in this customer segment.
- Weakness in capital equipment purchases across the industry, reflecting broader market hesitations.
- Continued market challenges in China, contributing to regional revenue declines and impacting overall performance.
Good day, ladies and gentlemen, and welcome to Repligen Corporation's First Quarter 2024 Earnings Conference Call. My name is Keith, and I will be your coordinator today. (Operator Instructions) Please note this event is being recorded. (Operator Instructions)
I would now like to turn the call over to your host for today's call, Sondra Newman, Head of Investor Relations. Please go ahead, ma'am.
Thank you, operator, and welcome to our first quarter of 2024 report. On this call, we will cover business highlights and financial performance for the 3-month period ending March 31, 2024, and will provide financial guidance for the year. Joining us on the call today are Repligen's CEO, Tony Hunt; our CFO, Jason Garland; and our Chief Commercial Officer, Olivier Loeillot.
As a reminder, the forward-looking statements that we make during this call, including those regarding our business goals and expectations for the financial performance of the company are subject to risks and uncertainties
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
